ArticleInternational journal of women's health2025
High-Risk Pregnancy with Solid Pseudopapillary Tumor of the Pancreas Complicated by Obstetric Antiphospholipid Syndrome: A Case Report.
Article in International journal of women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antiphospholipid syndrome(APS) is a common cause of recurrent miscarriage.This case report presents a rare case of a high-risk pregnancy complicated by the concurrent solid pseudopapillary neoplasm (SPN) and obstetric antiphospholipid syndrome (OAPS). Case: A 35-year-old patient was diagnosed with SPN at the age of 27, accompanied by extensive abdominal metastases, and underwent palliative metastatic tumor resection and chemotherapy, achieving stable disease. After a 24-month treatment-free interval, pregnancy was attempted. She had a history of five adverse pregnancy outcomes (one intrauterine fetal demise at 28 weeks, three instances of embryonic arrest, and one biochemical pregnancy). OAPS was diagnosed based on persistent positivity (≥12 weeks apart) for lupus anticoagulant, anti-β2 glycoprotein I antibody, and anti-cardiolipin antibody. Following a multidisciplinary evaluation, she was treated with a combination of tacrolimus, hydroxychloroquine, and prednisone to control antibody levels before planning for pregnancy. During the pregnancy, low molecular weight heparin combined with aspirin was administered, and ultimately, a healthy live baby was delivered via cesarean section at 36 weeks of gestation, with favorable maternal and neonatal outcomes. Currently, the patient remains disease-free with regular oncology follow-up and has preserved ovarian function. Conclusion: This case suggests that for patients with tumors and pathological pregnancies, screening for the presence of antiphospholipid syndrome should be emphasized. Although SPN poses risks such as tumor growth and hemorrhage during pregnancy, patients with long-term stable disease may attempt pregnancy under close monitoring. It is important to balance the risks of anticoagulation with those of tumor-related bleeding during pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.